Prostate cancer is the most frequently diagnosed cancer in men and a leading cause of cancer death in men. During 2007, the American Cancer Society estimates there will be 218,890 new cases of prostate cancer diagnosed and an estimated 27,050 deaths associated with the disease in the United States.  Long-term clinical data has shown that brachytherapy provides a minimally invasive treatment option with results equal to or better than other treatments.

Theragenics’, a leader in the market, has treated over 100,000 men for prostate cancer since 1987 when TheraSeed®, its premiere palladium-103 brachytherapy device, was introduced. Today, in addition to TheraSeed®, Theragenics offers I-Seed, an I-125  brachytherapy device, related brachytherapy products such as needles and spacers, and in-house loading and stranding services.